Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 2, 2019
Reporting Period: Year and quarter ended December 31, 2018
Status: Emerging Growth Company (Elected not to use extended transition period for new accounting standards)
Key Financial Metrics
This Form 8-K serves as a notification of the issuance of a press release regarding financial results. The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained in the referenced press release (Exhibit 99.1), which is incorporated by reference but not reproduced in the provided text.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the body text. It directs readers to the press release for the announcement of results for the year and quarter ended December 31, 2018.
Guidance, Outlook, and Risks
Management Commentary: The filing notes the issuance of a press release on April 2, 2019, but does not include the text of the commentary, guidance, or outlook.
Risks and Contingencies: No specific risks or contingencies are detailed in this 8-K text. The filing includes a standard disclaimer that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated April 2, 2019) for specific financial figures (revenue, net loss, cash position) as they are not present in the 8-K text.
- Verify the company's status as an Emerging Growth Company and its election regarding the extended transition period for accounting standards.
- Confirm the exact date of the financial results announcement (April 2, 2019) for the period ended December 31, 2018.
- Note that the financial data in the press release is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.